AAI101 is a novel beta-lactamase inhibitor primarily utilized in pharmaceutical research and development for combating multidrug-resistant bacterial infections. It specifically targets beta-lactamase enzymes produced by bacteria, which confer resistance to beta-lactam antibiotics such as penicillins and cephalosporins. By inhibiting these enzymes, AAI101 enhances the efficacy of existing antibiotics, particularly in combination therapies against resistant strains. Ongoing studies evaluate its safety, pharmacokinetics, and potential as a new therapeutic agent in preclinical and clinical settings to address unmet needs in infectious disease treatment.